Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 182 ()
DOP62: A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Reinisch*1, B. I. Jang2, V. Borzan3, A. Lahat4,5, A. Pukitis6, M. Osipenko7, Y. Mostovoy8, S. Schreiber9, S. Ben-Horin10, S. J. Lee11, J. H. Suh11, S. G. Lee11, J. H. Lee11, B. D. Ye12

1Medical University Vienna, Vienna, Austria, 2Yeungnam University Hospital, Daegu, South Korea, 3Clinical Hospital Center Osijek, Osijek, Croatia, 4Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 5Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Pauls Stradins Clinical University Hospital, Rīga, Latvia, 7Novosibirsk State Medical University, Novosibirsk, Russian Federation, 8Private Small_Scale Enterprise Medical Centre ‘Pulse’, Vinnytsya, Ukraine, 9University Hospital Schleswig-Holstein, Kiel, Germany, 10Sheba Medical Center, Tel Hashomer, Israel, 11Celltrion, Inc., Incheon, South Korea, 12Asan Medical Center, Seoul, South Korea

DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multi-centre, prospective, observational cohort studyECCO '19 Copenhagen
Year: 2019
Authors: G. Pineton de Chambrun1, B. Pariente2, P. Seksik3, R. Altwegg1, L. Vuitton4, C. Stefasnescu5, S. Nancey6, A. Aubourg7, M. Serrero8, L. Peyrin-Biroulet9, J. Filippi10, S. Viennot11, V. Abitbol12, M. Boualit13, A. Boureille14, J. Moreau15, A. Buisson16, X. Roblin17, M. Nachury2, M. Zappa18, J. Lambert19, Y. Bouhnik5, GETAID-MICA studygroup1

1Montpellier University Hospital, Gastroenterology, Montpellier, France, 2Lille University Hospital, Gastroenterology, Lille, France, 3Saint-Antoine University Hospital, Gastroenterology, Paris, France, 4Besançon University Hospital, Gastroenterology, Besançon, France, 5Beaujon University Hospital, Gastroenterology, Clichy, France, 6Lyon University Hospital, Gastroenterology, Lyon, France, 7Tours University Hospital, Gastroenterology, Tours, France, 8Marseille University Hospital, Gastroenterology, Marseille, France, 9Nancy University Hospital, Gastroenterology, Vandoeuvre-les-Nancy, France, 10Nice University Hospital, Gastroenterology, Nice, France, 11Caen University Hospital, Gastroenterology, Caen, France, 12Cochin University Hospital, Gastroenterology, Paris, France, 13Valenciennes General Hospital, Gastroenterology, Valenciennes, France, 14Nantes University Hospital, Gastroenterology, Nantes, France, 15Toulouse University Hospital, Gastroenterology, Toulouse, France, 16Clermont-Ferrand University Hospital, Gastroenterology, Clermont-Ferrand, France, 17Saint-Etienne University Hospital, Gastroenterology, Saint-Etienne, France, 18Beaujon University Hospital, Radiology, Clichy, France, 19Saint-Louis University Hospital, Biostatistics, Paris, France

DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

L-Y. Mak*1, L. Chen2, T. Tong2, S. Lau2, W-K. Leung2

1Queen Mary Hospital, Medicine, Hong Kong, Hong Kong, 2The University of Hong Kong, Medicine, Hong Kong, Hong Kong

DOP65: The association of faecal calprotectin level and combined mucosal and transmural healing in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Noh*1, E. H. Oh1, S. H. Park2,3, J. B. Lee4, J. Y. Kim1, J. C. Park1, J. Kim1, N. Ham1, E. M. Song1, S. H. Park1,3, S. W. Hwang1,3, D. H. Yang1, J. S. Byeon1, S. J. Myung1, S. K. Yang1,3, B. D. Ye1,3

1Asan Medical Center, Gastroenterology, Seoul, South Korea, 2Asan Medical Center, Radiology, Seoul, South Korea, 3Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, South Korea, 4Asan Medical Center, Clinical Epidemiology and Biostatistics, Seoul, South Korea

DOP66: Surveillance colonoscopies in ulcerative colitis: does it make a difference?

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Hu*1, G. Nguyen2, J. Rangrej3, J. Marshall1, N. Narula1

1McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, Canada, 2University of Toronto, Division of Gastroenterology, Mount Sinai Hospital, Toronto, Canada, 3Ministry of Health and Long-Term Care, Health Analytics Branch, Toronto, Canada

DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histological inflammation in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Klenske*1, R. Atreya1, A. Hartmann2, S. Fischer1, S. Hirschmann1, S. Zundler1, M. Iacucci3, M. Neurath1, T. Rath1

1University Hospital of Erlangen, Department of Medicine 1, Division of Gastroenterology, Erlangen, Germany, 2University Hospital of Erlangen, Institute of Pathology, Erlangen, Germany, 3University of Birmingham, Institute of Translational Medicine, Birmingham, UK

DOP68: Histological remission (NANCY index) is superior to endoscopic mucosal healing in predicting relapse-free survival in patients with ulcerative colitis in clinical and endoscopic remission

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Wang*1, I. Fewings2, L. Bornman1, B. Shadbolt3, M. Fadia2, K. Subramaniam1,4

1Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia, 2ACT Pathology, Canberra Hospital, Canberra, Australia, 3Health Analytics Research Centre, Canberra Hospital, Canberra, Australia, 4ANU Medical School, Australian National University, Canberra, Australia

DOP69: The detection with targeted biopsy and characterisation of neoplastic lesions by magnifying chromoendoscopy and NBI in surveillance colonoscopy of patients with ulcerative colitis: a sub-analysis of the Navigator Study

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Watanabe*1,2, M. Esaki3, S. Oka4, F. Shimamoto5, M. Nishishita2, T. Fukuchi6, S. Fujii7, F. Hirai8, K. Kakimoto9, T. Inoue9, H. Kashida10, K. Takeuchi11, N. Ohmiya12, M. Saruta13, S. Saito14, Y. Saito15, S. Tanaka16, Y. Ajioka17, H. Tajiri13

1Hyogo College of Medicine, Intestinal Inflammation Research, Nishinomiya, Japan, 2Nishishita GI Hospital, Osaka, Japan, 3Saga University, Saga, Japan, 4Hiroshima University, Hiroshima, Jamaica, 5Prefectural University of Hiroshima, Hiroshima, Japan, 6Osakafu Saiseikai Nakatsu Hospital, Osaka, Japan, 7Kyoto Katsura Hospital, Kyoto, Japan, 8Fukuoka University Chikushi Hospital, Fukuoka, Japan, 9Osaka Medical College, Osaka, Japan, 10Kinki University, Osaka, Japan, 11Toho University Sakura Medical Center, Chiba, Japan, 12Fujita Medical University, Aichi, Japan, 13The Jikei University School of Medicine, Tokyo, Japan, 14The Cancer Institute Hospital of JFCR, Tokyo, Japan, 15National Cancer Center Hospital, Tokyo, Japan, 16Hiroshima University, Hiroshima, Japan, 17Niigata University, Niigata, Japan

DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Verstockt*1,2, P. Sudahakar2,3,4, B. Creyns5, S. Verstockt6, J. Cremer5, W-J. Wollants2, S. Organe2, T. Korcsmaros3,4, M. Madgwick3, G. Van Assche1,2, C. Breynaert5, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3Earlham Institute, Norwich, UK, 4Quadram Institute, Norwich, Belgium, 5KU Leuven, Department of Microbiology and Immunology, Laboratory of Clinical Immunology, Leuven, Belgium, 6KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium

DOP71: Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Li*1, J. R. Friedman1, C. Marano1, H. Zhang1, F. Yang1, B. G. Feagan2, L. Peyrin-Biroulet3, G. De Hertogh4

1Janssen Research and Development, LLC, Spring House, USA, 2Robarts Research Institute, Robarts Clinical Trials, London, Canada, 3Nancy University Hospital, Université de Lorraine, Nancy, France, 4University Hospitals KU, Leuven, Belgium

DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia

ECCO '19 Copenhagen

Year: 2019
Authors:

M. de Jong*1, H. Kanne1, L. Nissen2, I. Nagtegaal3, J. Drenth1, L. Derikx1,2, F. Hoentjen1

1Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands, 2Jeroen Bosch Hospital, Gastroenterology and Hepatology, s'Hertogenbosch, The Netherlands, 3Radboud University Medical Center, Pathology, Nijmegen, The Netherlands

DOP73: Treatment of perianal fistulas in Crohn’s disease, seton vs. anti-TNF vs. surgical closure following anti-TNF (PISA): a randomised controlled trial

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Wasmann*1, E. J. de Groof2, M. Stellingwerf1, G. D'Haens3, C. Ponsioen3, K. Gecse3, M. Dijkgraaf4, W. Bemelman2, C. Buskens2

1Amsterdam UMC, Department of Surgery and Gastroenterology, Amsterdam, The Netherlands, 2Amsterdam UMC, Department of Surgery, Amsterdam, The Netherlands, 3Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 4Amsterdam UMC, Clinical Research Unit and Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam, The Netherlands

DOP74: Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Biron*1, P. Seksik2, M. Nachury3, Y. Bouhnik4, A. Amiot5, S. Viennot6, M. Serrero7, M. Fumery8, M. Allez9, L. Siproudhis10, A. Buisson11, G. Pineton de Chambrun12, V. Abitbol13, S. Nancey14, L. Caillo15, L. Plastaras16, L. Armengol-Debeir17, E. Chanteloup18, M. Simon19, N. Dib20, S. Rajca21, M. Amil22, L. Peyrin-Biroulet23, L. Vuitton24

1CHU Jean Minjoz, Gastroenterology, Besançon, France, 2Hôpital Saint-Antoine, Gastroentérologie, Paris, France, 3CHRU Lille, Gastroentérologie, Lille, France, 4Hôpital Beaujon, AP-HP, Gastroentérologie, Paris, France, 5Hôpital Henri-Mondor, Gastroentérologie, Paris, France, 6CHRU Caen, Gastroentérologie, Caen, France, 7APHM Hôpital Nord, Gastroentérologie, Marseille, France, 8CHRU Amiens, Gastroentérologie, Amiens, France, 9Hôpital Saint-Louis, AP-HP, Gastroentérologie, Paris, France, 10CHRU Rennes, Gastroentérologie, Rennes, France, 11CHRU Clermont-Ferrand, Gastroentérologie, Clermont-Ferrand, France, 12CHRU Montpellier, Gastroentérologie, Montpellier, France, 13Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, 14Groupement Hospitalier Sud Hospices Civils de Lyon, Gastroentérologie, Lyon, France, 15CHU Nîmes, Gastroentérologie, Nîmes, France, 16Hôpital Pasteur, Gastroentérologie, Colmar, France, 17CHRU Rouen, Gastroentérologie, Rouen, France, 18Hôpital Saint-Joseph, Gastroentérologie, Paris, France, 19Institut Mutualiste Monsouris, Gastroentérologie, Paris, France, 20CHRU Angers, Gastroentérologie, Angers, France, 21Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, 22CHD Vendée, Gastroentérologie, La Roche-sur-Yon, France, 23CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, 24CHRU Jean Minjoz, Gastroentérologie, Besançon, France

DOP75: Surgery and hospitalisations rates in inflammatory bowel disease patients in the Québec provincial database from 199–6 to 2015

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Verdon*1, J. Reinglas1, J. Coulombe2, L. Gonczi3, T. Bessissow1, W. Afif1, M. Vutcovici4, G. Wild1, E. Seidman1, A. Bitton1, P. Brassard5,6, P. Lakatos1

1McGill University Health Center, Division of Gastroenterology, Montreal, Canada, 2Lady Davis Research Institute, Jewish General Hospital, Centre for Clinical Epidemiology, Montreal, Canada, 3Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, 4McGill University Health Centre, Division of Gastroenterology, Montreal, Canada, 5Biostatistics and Occupational Health, Department of Epidemiology, Montreal, Canada, 6McGill University, Department of Medicine, Montreal, Canada

DOP76: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease in a nationwide cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Nordholm-Carstensen*1, N. Qvist2, B. Højgaard3, C. Halling3, M. Carstensen4, N-P. Ipland4, J. Burisch5

1Zealand University Hospital, Department of Surgery, Roskilde, Denmark, 2Odense University Hospital, Department of Surgery, Odense, Denmark, 3VIVE – The Danish Center for Social Science Research, Copenhagen, Denmark, 4Takeda Pharma A/S, Taastrup, Denmark, 5Danish Centre for eHealth and Epidemiology, Frederikssund, Denmark

DOP77: The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's disease

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Knyazev1, A. Kagramanova*1, A. Lishchinskaya1, M. Zvyaglova1, D. Kulakov1, A. Parfenov1

1Moscow Clinical Scientific Center named after A. S. Loginov, Department of Inflammatory Bowel Diseases, Moscow, Russian Federation

DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Biron*1, P. Seksik2, M. Nachury3, S. Nancey4, Y. Bouhnik5, M. Serrero6, L. Armengol-Debeir7, A. Buisson8, M-L. Tran Minh9, C. Zallot10, M. Fumery11, G. Bouguen12, V. Abitbol13, S. Viennot14, E. Chanteloup15, S. Rajca16, N. Dib17, L. Peyrin-Biroulet10, L. Vuitton18

1CHU Jean Minjoz, Gastroenterology, Besançon, France, 2Hôpital Saint-Antoine, Gastroentérologie, Paris, France, 3CHRU Lille, Gastroentérologie, Lille, France, 4Groupement Hospitalier Sud Hospices Civils de Lyon, Gastroentérologie, Lyon, France, 5Hôpital Beaujon, AP-HP, Gastroentérologie, Paris, France, 6APHM Hôpital Nord, Gastroentérologie, Marseille, France, 7CHRU Rouen, Gastroentérologie, Rouen, France, 8CHRU Clermont-Ferrand, Gastroentérologie, Clermont-Ferrand, France, 9Hôpital Saint-Louis, AP-HP, Gastroentérologie, Paris, France, 10CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, 11CHRU Amiens, Gastroentérologie, Amiens, France, 12CHRU Rennes, Gastroentérologie, Rennes, France, 13Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, 14CHRU Caen, Gastroentérologie, Caen, France, 15Hôpital Saint-Joseph, Gastroentérologie, Paris, France, 16Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, 17CHRU Angers, Gastroentérologie, Angers, France, 18CHRU Jean Minjoz, Gastroentérologie, Besançon, France

DOP79: Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials

ECCO '19 Copenhagen

Year: 2019
Authors:

B. G. Feagan*1, B. E. Sands2, R. Lirio3, T. Lissoos3, J. Wang3, D. Feng3, K. Lasch3

1Robarts Clinical Trials, Western University, London, Ontario, Canada, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, NY, USA, 3Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA

DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Buisson*1, D. Laharie2, S. Nancey3, X. Hébuterne4, X. Roblin5, M. Nachury6, L. Peyrin-Biroulet7, M. Fumery8, F. Goutorbe1, D. Coban1, C. Allimant1, M. Reymond1, E. Vazeille1, B. Pereira1, M. Goutte1, G. Bommelaer1

1University Hospital Estaing, IBD unit, Clermont-Ferrand, France, 2CHU Bordeaux, Bordeaux, France, 3HCL Lyon-Sud, Lyon, France, 4CHU Nice, Nice, France, 5CHU Saint-Etienne, Saint-Etienne, France, 6CHU Lille, Lille, France, 7CHU Nancy, Nancy, France, 8CHU Amiens, Amiens, France

DOP81: Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. L. Hamilton*1, P. P. De Cruz1,2, E. K. Wright3, L. Okada4, M. Hale4, L. Mimms4, A. Jain4, M. A. Kamm1

1The University of Melbourne and St Vincent's Hospital, Melbourne, Department of Medicine and Department of Gastroenterology, Melbourne, Australia, 2Austin Health, Department of Gastroenterology, Melbourne, Australia, 3St Vincent's Hospital, Department of Gastroenterolgy, Melbourne, Australia, 4Prometheus Laboratories Inc., San Diego, USA

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 182 ()